Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need an implantable cardioverter-defibrillator for primary prevention?

Autor:	Magdy Abdelhamid, Giuseppe Rosano, Marco Metra, Stamatis Adamopoulos, Michael Böhm, Ovidiu Chioncel, Gerasimos Filippatos, Ewa A. Jankowska, Yury Lopatin, Lars Lund, Davor Milicic, Brenda Moura, Tuvia Ben Gal, Arsen Ristic, Amina Rakisheva, Gianluigi Savarese, Wilfried Mullens, Massimo Piepoli, Antoni Bayes‐Genis, Thomas Thum, Stefan D. Anker, Petar Seferovic, Andrew J.S. Coats
Přispěvatelé:	Publica
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Heart Failure Receptors Angiotensin Sudden death Angiotensin II Adrenergic beta-Antagonists Heart failure with reduced ejection fraction Implantable cardioverter-defibrillator Angiotensin-Converting Enzyme Inhibitors Stroke Volume Ventricular Function Left Defibrillators Implantable Primary Prevention Angiotensin Receptor Antagonists Norepinephrine Death Sudden Cardiac Humans Neprilysin Cardiology and Cardiovascular Medicine Aldosterone Sodium-Glucose Transporter 2 Inhibitors Mineralocorticoid Receptor Antagonists
Zdroj:	European Journal of Heart Failure r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname
ISSN:	1388-9842
Popis:	Sudden death is a devastating complication of heart failure (HF). Current guidelines recommend an implantable cardioverter-defibrillator (ICD) for prevention of sudden death in patients with HF and reduced ejection fraction (HFrEF) specifically those with a left ventricular ejection fraction
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ac6a89229aad5483e7fc1bc7936138 https://publica.fraunhofer.de/handle/publica/429673 Zobrazit plný text záznamu Plný text